Asher Bio Closes $55 Million Series C Financing
WEB Asher Biotherapeutics Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trial
Leading biotech company Asher Bio announced today the successful closing of its $55 million Series C financing round. This significant investment will enable Asher Bio to advance its lead program into Phase 1b clinical trials, marking a major milestone in the company's mission to deliver transformational cancer therapies.
Asher Bio is a cutting-edge biotechnology company dedicated to developing precisely targeted immunotherapies for cancer and other diseases. With its innovative technology, Asher Bio aims to revolutionize cancer treatment by harnessing the power of the immune system to selectively target and eliminate tumors.
The lead program, currently in preclinical development, has demonstrated promising results in animal models. The Phase 1b clinical trial will assess the safety, tolerability, and efficacy of the lead program in patients with advanced cancer.
"This Series C financing validates our scientific approach and enables us to aggressively pursue our clinical development plans," said Dr. Peter Mullin, CEO of Asher Bio. "We are committed to bringing our transformative therapies to patients as quickly as possible, and this funding will empower us to take the next critical steps toward that goal."
The Series C financing was led by a syndicate of top-tier healthcare investors, including OrbiMed, Novo Holdings, and BVF Partners. This investment underscores the confidence of the investment community in Asher Bio's technology and its potential to revolutionize cancer treatment.
Pinterest
Pinterest
Comments